Nicoletta Colombo, MD, European Institute of Oncology, Milan, Italy, presents the main findings of the Phase III KEYNOTE-826 clinical trial (NCT03635567) evaluating the addition of pembrolizumab to chemotherapy with or without bevacizumab in patients with recurrent persistent or metastatic cervical cancer. The results show improved outcomes for the pembrolizumab arm in all endpoints, including progression-free survival (PFS), overall survival (OS), response rate (RR), duration of response (DOR) and quality of life (QoL), independent of PD-L1 status and of addition of bevacizumab. In addition, results were consistent across a set of defined subgroups. These results support the addition of pembrolizumab in standard of care treatment for this patient population. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.